Imagination at work.

Alex Gibson, Head of Research Alliances GE Healthcare Life Sciences

Life Sciences - Enabling Development & Production of Future Medicines

RESEARCH INSTRUMENTS & CONSUMABLES

REGENERATIVE MEDICINE & CELL TECHNOLOGIES

BIOPROCESSING CAPACITY & CAPABILITY

MOLECULAR & IN-VITRO

DIAGNOSTICS

CLINICAL IMAGING

DISCOVERY PRE-CLINICAL &

CLINICAL DEVELOPMENT

APPROVAL & COMPANION DIAGNOSTICS

THERAPY SELECTION & MONITORING

3 JSB Earnings 101714

GE Healthcare Life Sciences Addressing tomorrow’s needs today

3

3

Enabling Precision Medicine with Precision Diagnostics

Industrializing Tools & Systems for Regenerative Medicine

Enabling Biotech and Pharma Research

Driving Biopharma

Capacity & Productivity

Biopharmaceutical market growing 8% CAGR (‘12-’16F)

6 of the top 10 drugs are Biopharmaceuticals

Emerging market demand for diagnostics & biopharma manufacturing

Precision medicine in the future

A century of ‘mass market’ medicine comes to an end…

Moving to ‘personalized’ patient-based decisions

Precision medicine needs precision diagnostics and uses all available clinically useful data

Typically 40% to 75% of cancers do not

respond to bio-marker targeted therapies

Match a patient’s disease to the best

diagnosis & treatment

Therapies should have an accompanying

biomarker

Biomarker combinations & multiple-

parameter tests increase response rates

5

Clinical evidence-based value & utility will detemine price Development cost in

evidence generation Must serve global patient, not just US & Europe

6

From content – in vivo and in vitro information (e.g., biomarkers, companion diagnostics)

And generated by technology (e.g. PET, sequencing, Multiomyx) and analytics (e.g. bioinformatics, integrated reporting)

What Are ‘Precision Diagnostics’?

‘Precision diagnostics’ = actionable diagnostic information that enables precision medicine

From single biomarkers to integrated data

Why Precision Diagnostics?

To enable:

Earlier & more accurate diagnoses- often before symptoms develop

Treatment that is right for the individual

Improved compliance and outcomes

System savings of $ billions in unnecessary tests and ineffective treatment

Pharma to conduct smaller, faster, cheaper & more successful clinical trials

Quality… Affordability…Access

7

Demand From Driven By

• Physicians • Complexity

• Patients • Outcomes

• Payors • Cost

• Pharma • New therapy development

Diagnostic data get more complex … but can provide far better therapy guidance than ever before

Personalized Medicine

“Relatively Easy” Dx • Single Sample • Single Result

• Single Interpretation

• Lower value/reimburse.

• Low hurdle reg. approv.

“Complex” Dx • Multi-omics

• Multiplexed

• Multisource interpretation

• High Value/reimburse. risk

• Regulated based on risk

Is there something?

Molecular pathway?

Which stage?

Which subtype?

What is it?

Risk profile?

Which treatment will work?

Is it under control?

The Past The Future

Diagnostics for Successful Therapeutic Outcome

9

Precision Dx technology offerings

Global Challenges Clinical Utility

DMD Availability Reimbursement

Dementia Landscape – rapidly developing

0

10

20

30

40

50

60

70

N u

m b

e r o f d r

u g

s

Phase 1

Phase 2

Phase 3

Launched

NT Release

Amyloid Modulator

Tau Modulator

Unknown Neuro Protection

Market Feedback: • Disease modifying drugs (DMD) struggle to

reach market; no objective criteria • Biomarker Diagnostics without therapy is

challenging

• Diagnostics are failing to get reimbursement • Therapy without Biomarker Diagnostics is

challenging

• Both Pharma and Imaging need a model to work together to accelerate products

Improved patient outcomes increasingly dependent on combination diagnostic & therapy Pharma & diagnostic industry need to collaborate to pro-

actively manage care across disciplines

For Neuroscience research, anatomical location makes PET neurology imaging a natural companion to therapy development

12

Improved patient outcomes at lower

cost

Assess multiple parameters

• e.g. Lesion size, fuzzy vs. smooth edges, composition

Combine with in-vitro and other patient data

Demonstrate clinical utility

Take net-cost out of the care pathway

Precision Diagnostics

GE’s MultiOmyxTM

Multi-molecular multiplexing

Assess proteins & other molecules

(DNA) at a single-cell level

Maximizes limited tissue sample examining < 175 proteins

1st offered in Hodgkin’s Lymphoma

13

Enable clinical development Better patient selection & target engagement

Better understanding of PK/PD parameters

Companion diagnostic development

Competitive differentiator Better knowledge of disease & improved health

economics

Better therapeutic efficiency & improved reimbursement

Participate in value creation Directly influence diagnostic R&D and invest in segment

of future growth

GE PET tracers in amyloid, tau & neuro-inflammation

Precision diagnostics enables therapeutic development

14

The Benefits of the Neuroincubator R&D Past vs Present

Discovery Clinical Trials

Clinical Research

Clinical Product

PET Amyloid - DMD studies started just before approval

2000 2002 2003 2005 2007 2009 2010 2012 2008 2011 2013

Discovery

Pittsburgh

PiB / F-18

In-licensing

Phase I

(2007/8)

Approval

Oct ’13

Phase II

(2008/9)

Phase III

(2009 - 11)

Discovery Clinical Research Clinical Trials

Clinical Product

PET Tau – DMD studies could start during PoC (phase II)

Support DMD

Devt.

AIM: Support DMD Development

10+ years at GE

Earlier Access to PET Tau ligand for DMD Development Studies

Neuroincubator

Clinical Potential But … Uncertainty

Proven Clinical Application

Neuroincubator

GE Healthcare Life Sciences –Core Imaging R&D

Pharma

Materials, methods, licenses, know-how Data, clinical

insight

Academics

• Open Innovation model with early and broad access to GEHC PET tracers to

enable investigator-led clinical research

• Three tracers currently available: GE-179 NMDA, GE-180 Neuroinflammation,

GE-216 (THK5351) Tau

Collaborative groups to accelerate qualification for therapeutic drug development

Opportunity for research community to access interesting research tools early to explore multiple applications

Autologous Therapy – Emerging Therapeutic Modality

Autologous Therapies

Scale out

Tissue

Engineering

Cellular

Immunotherapy

Gene

Therapies

iPSCs

Big Data

18

Data data everywhere… 1750-present

1750 Industrial Revolution

1950

continuous combustion engine that is the basis for the gas turbine

1750-1950: Rise industrial machines, fleets and networks

1965-1980 Creation of ArpaNet and other precursors to the Internet

1990-2010: Rise of personal computers; World Wide Web, private networks; e-commerce and eventually social media

Big data and the cloud emerge

Internet Revolution

1960 2010

1950s: Rise of Mainframe computers

2012-and beyond: Expansion of the Internet across industrial enterprises

Intelligent devices

Intelligent networks

Intelligent automation

Industrial Internet

Future

networks

Advanced machines

Fleets

Historic Waves of innovation and productivity

Global data boom

55% of the datacenters that will be processing data

around the world in 2025 have not yet been built

Data production will be 44X greater in 2020 than it was

in 2009

Big data market estimated to be $16.9B in 2015

Source: IDC

Source: Wikibon

Precision Dx + Big Data + Industrial Internet

Integrate huge diverse data sets

Transform multiple data sets into actionable information

Analytics to enable sharper insights & improve performance

Unexpected insights & gains become commonplace

21

All the available relevant data to make the best possible decision for this patient now

Radiology

Risk profile

Family history

Medical records

Behavioural data

In-vitro diagnostics

Genomic sequencing

Pathology & tissue analysis

Multi-drug interaction data

Long-term population outcomes

Aggregated Google search data?

What more? 22

Precision medicine makes non-clinical demands

Physician & patient care

Understand

complex Dx

pathways

Effective use of

clinical decision

tools

Payor & policymaker

Forward-thinking

proactivity in

approvals

Holistic health-

economic

thinking

Pharma & biotech

Re-think R&D,

and partnership

More openness &

collaboration

Demonstrate

real value

Title or Job Number | XX Month 201X 23

Innovate, refine, improve, collaborate

Alex Gibson – Head of Research Alliances Core Imaging R&D Alex.gibson@ge.com